154 related articles for article (PubMed ID: 29473335)
1. Leptomeningeal enhancement on preoperative brain MRI in patients with glioblastoma and its clinical impact.
Kim H; Lim DH; Kim TG; Lee JI; Nam DH; Seol HJ; Kong DS; Choi JW; Suh YL; Kim ST
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e366-e373. PubMed ID: 29473335
[TBL] [Abstract][Full Text] [Related]
2. Postoperative disappearance of leptomeningeal enhancement around the brainstem in glioblastoma.
Inoue H; Kuroda JI; Uetani H; Matsuyama T; Kaku Y; Shinojima N; Hirai T; Mukasa A
Neuroradiology; 2024 Mar; 66(3):325-332. PubMed ID: 38200284
[TBL] [Abstract][Full Text] [Related]
3. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Nowosielski M; Ellingson BM; Chinot OL; Garcia J; Revil C; Radbruch A; Nishikawa R; Mason WP; Henriksson R; Saran F; Kickingereder P; Platten M; Sandmann T; Abrey LE; Cloughesy TF; Bendszus M; Wick W
Neuro Oncol; 2018 Mar; 20(4):557-566. PubMed ID: 29016943
[TBL] [Abstract][Full Text] [Related]
4. Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade.
Lakomy R; Kazda T; Selingerova I; Poprach A; Pospisil P; Belanova R; Fadrus P; Vybihal V; Smrcka M; Jancalek R; Hynkova L; Muckova K; Hendrych M; Sana J; Slaby O; Slampa P
Front Oncol; 2020; 10():840. PubMed ID: 32719739
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY
Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354
[TBL] [Abstract][Full Text] [Related]
6. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
7. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
8. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
9. Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial.
Field KM; Fitt G; Rosenthal MA; Simes J; Nowak AK; Barnes EH; Sawkins K; Goh C; Moffat BA; Salinas S; Cher L; Wheeler H; Hovey EJ; Phal PM;
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e359-e365. PubMed ID: 29114999
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
11. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
12. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Sepúlveda JM; Belda-Iniesta C; Gil-Gil M; Pérez-Segura P; Berrocal A; Reynés G; Gallego O; Capellades J; Ordoñez JM; La Orden B; Balañá C
Clin Transl Oncol; 2015 Sep; 17(9):743-50. PubMed ID: 26033428
[TBL] [Abstract][Full Text] [Related]
14. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
15. Impact on survival of early tumor growth between surgery and radiotherapy in patients with de novo glioblastoma.
De Barros A; Attal J; Roques M; Nicolau J; Sol JC; Cohen-Jonathan-Moyal E; Roux FE
J Neurooncol; 2019 May; 142(3):489-497. PubMed ID: 30783874
[TBL] [Abstract][Full Text] [Related]
16. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
17. Leptomeningeal spread in high-grade gliomas: Is surgery or adjuvant therapy after leptomeningeal spread associated with survival benefit?
Zhong S; Fu X; Wu C; Liu R; Li S
Neurosurg Rev; 2023 Nov; 46(1):311. PubMed ID: 37993665
[TBL] [Abstract][Full Text] [Related]
18. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
[TBL] [Abstract][Full Text] [Related]
19. Impact of removed tumor volume and location on patient outcome in glioblastoma.
Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
[TBL] [Abstract][Full Text] [Related]
20. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
Blumenthal DT; Mendel L; Bokstein F
J Neurooncol; 2016 May; 127(3):493-502. PubMed ID: 26721244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
